High-Grade Glioma, NOS
Associated Genetic Biomarkers
High-grade glioma, NOSs most frequently harbor alterations in TP53, CDKN2A, CDKN2B, ATRX, and IDH1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 c.142-c.212 Missense, TP53 c.1-c.137 Missense, and TP53 Missense are the most common alterations in high-grade glioma, NOS .
There is 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are completed or closed. Of the trial that contains high-grade glioma, NOS as an inclusion criterion, 1 is phase 1 (1 open).
Therapeutic autologous lymphocytes is the most common intervention in high-grade glioma, NOS clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.